A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
← catalyst calendarNCT05831111 · readout in 55 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
482actual
Sites
34
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-05 | actual | When the study began enrolling |
| Primary completion | 2026-10-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-13 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Epstein-Barr Virus Infection
Interventions
- Biological: mRNA-1195.1
- Biological: mRNA-1195.2
- Biological: mRNA-1189
- Biological: Placebo
- Biological: mRNA-1195
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
measured Up to Day 176 (7-day follow-up after vaccination)
Number of Participants with Unsolicited Adverse Events (AEs)
measured Up to Day 197 (28-day follow-up after vaccination)
Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Discontinuation of Study Intervention and/or Study Participation, and AEs of Special Interest (AESIs)
measured Part A and B: Day 1 to end of study (EOS) (Part A: Day 337; Part B: Day 505)
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed